If your antitrust compliance program hinges on proving your company had no intent to harm competition, you're focusing on the wrong standard. The FTC's recent amicus brief in a case against Johnson & Johnson clarifies this: antitrust enforcement is about the effect of conduct, not the motivation behind it.
These myths persist because intent seems intuitive. We're used to criminal law frameworks where motive matters. But antitrust law operates differently, and this should reshape how you train your teams, assess risk, and document decisions.
Myth 1: If We Can Show We Didn't Intend to Harm Competition, We're Protected
Reality: The Sherman Act and Clayton Act evaluate competitive harm based on market effects, not corporate motivation.
The FTC's brief in the Johnson & Johnson case states this clearly: binding precedent focuses on the effect on competition and harm to consumers, not on proof of specific intent to harm competition. The case involves allegations that Johnson & Johnson maintained a monopoly on Stelara through acquisition and patent assertion strategies. Whether executives intended to block competitors is legally irrelevant if the conduct actually blocked them.
This matters for your documentation practices. Email trails showing "we're just trying to maximize shareholder value" don't protect you. Courts will examine whether your pricing strategy, exclusive dealing arrangement, or acquisition actually foreclosed competition, regardless of what your board minutes say about intent.
Train your commercial teams on this distinction. A product manager who believes good intentions justify aggressive tactics is a compliance risk.
Myth 2: Our Lawyers Review Major Deals, So We're Covered
Reality: Legal review of a transaction under the Hart-Scott-Rodino Act addresses merger notification requirements, not ongoing competitive conduct.
Hart-Scott-Rodino requires pre-merger filings for transactions above certain thresholds, but clearing that hurdle doesn't mean your post-acquisition conduct gets a pass. The Johnson & Johnson allegations involve the acquisition of Momenta Pharmaceuticals and what happened after: how the combined entity used its patent portfolio.
Your compliance program should address the integration period. When two sales forces merge, are you training the combined team on customer allocation rules? When you consolidate supplier contracts, are you reviewing whether the new terms create exclusive arrangements that foreclose rivals? These questions don't get answered in the initial HSR filing.
Map your post-merger compliance touchpoints. Identify when commercial decisions shift from "we're integrating two companies" to "we're using our combined market position." That's where competitive effects emerge.
Myth 3: We Only Need to Worry About Antitrust If We're the Market Leader
Reality: Market definition is fact-specific, and you can hold monopoly power in narrower markets than you think.
The Stelara case involves a drug treating specific autoimmune conditions. The relevant market isn't "all pharmaceuticals" or even "all autoimmune treatments." It's the specific therapeutic category where substitutes are limited.
Your company might hold significant power in a geographic region, a customer segment, or a product subcategory even if you're small nationally. A regional hospital network can monopolize local markets. A component manufacturer can dominate a specialized input.
Conduct market share analysis at the level where your customers actually make decisions. If your sales team talks about "owning" a territory or category, test whether that language reflects actual market power. If it does, your conduct in that market gets scrutiny.
Myth 4: Our Compliance Training Covers Antitrust Because We Have a Module on Price-Fixing
Reality: Most antitrust training focuses on horizontal agreements between competitors and ignores unilateral conduct by dominant firms.
Price-fixing, bid-rigging, and market allocation between competitors are critical topics. But if your company holds significant market share, you also need training on monopolization and exclusionary conduct. That's a different skill set.
Your product managers need to understand when a loyalty discount becomes an exclusive dealing arrangement that forecloses competition. Your licensing team needs to recognize when patent assertion crosses into anticompetitive territory. Your sales leaders need to know that tying products together can violate the Clayton Act if you have market power in the tying product.
Segment your training by role and market position. A company with 15% market share needs different content than one with 60%.
Myth 5: If the Conduct Has a Legitimate Business Justification, We're Safe
Reality: Business justifications are weighed against anticompetitive effects; they don't provide automatic immunity.
You'll hear "but we have a legitimate reason" in nearly every antitrust investigation. The question isn't whether a justification exists, but whether it outweighs the competitive harm and whether less restrictive alternatives were available.
Consider exclusive supply agreements. You might have legitimate reasons: ensuring quality, protecting trade secrets, guaranteeing volume. Courts will still ask whether the exclusivity forecloses enough of the market to harm competition, and whether you could achieve your goals through shorter terms or narrower restrictions.
Document your decision-making process, but don't stop at justification. Show that you considered alternatives. Show that you assessed market impact. Show that you chose the least restrictive option that met your business needs.
What to Do Instead
Build your antitrust compliance program around competitive effects, not corporate intent.
Start with market assessment. Where does your company hold significant share? In those markets, implement enhanced protocols for pricing decisions, customer terms, and competitor interactions. You don't need the same controls in markets where you're a small player.
Train on effects-based analysis. Teach your commercial teams to ask "how does this affect competition?" not "what's our motivation?" Use case studies that show how neutral-sounding practices, like long-term contracts or bundled pricing, can foreclose markets when you're dominant.
Review conduct, not just transactions. The FTC's brief emphasizes that anticompetitive conduct includes ongoing business practices, not just one-time deals. Audit your standard contract terms, discount structures, and partnership agreements for exclusionary effects.
Update your risk assessment. If you've been evaluating antitrust risk based on whether teams intend to harm competition, you're missing the actual legal standard. Assess whether your conduct could substantially lessen competition or tend to create a monopoly, regardless of motivation.
The Commission vote authorizing the FTC's brief was 2-0, signaling clear regulatory consensus on this interpretation. Your compliance program should reflect the standard enforcers will actually apply: not what you intended, but what you did, and what effect it had on competition.
